Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176701 | 0.90 | CYP1A2 (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL24309160 | 0.87 | CYP1A2 (0.48) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL13250492 | 0.86 | GAA (0.46) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL3987200 | 0.86 | GAA (0.46) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL29023037 | 0.84 | GAA (0.45) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL11288753 | 0.84 | GAA (0.45) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL3209626 | 0.84 | GAA (0.45) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL23308128 | 0.84 | KDM4E (0.44) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL11074412 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL7682341 | 0.83 | L3MBTL1 (0.44) | GAAMGAMSIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674169-A | Preparation method of carbofuran derivatives | 湖南海利常德农药化工有限公司 | 2017-05-17 | — | — | CN | claimed |
| EP-0588655-B1 | Amidinophenol derivatives | ONO PHARMACEUTICAL CO (JP) | 1996-12-04 | — | — | EP | claimed |
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3892621-B1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-09-18 | — | — | EP | disclosed |
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023118319-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| CN-111434662-B | Haloallylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TransThera Sciences (Nanjing), Inc (CN) | 2022-03-17 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| US-5391731-A | Useful therapeutics for circulatory diseases | SUNTORY LIMITED (JP) | 1995-02-21 | — | — | US | disclosed |
| US-5206239-A | Cardiovascular disorders | SUNTORY LIMITED (JP) | 1993-04-27 | — | — | US | disclosed |
| EP-0441349-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4587353-A | Process for producing N-chlorosulfenyl compounds | CIBA-GEIGY CORPORATION (US) | 1986-05-06 | — | — | US | disclosed |
| US-4421693-A | INSECTICIDES, MITICIDES OR NEMATOCIDES | OTSUKA CHEMICAL CO., LTD. (JP) | 1983-12-20 | — | — | US | disclosed |
| US-4413005-A | 2,3-DIHYDRO-2,2-DIMETHYLBENZOFURAN-7-YL DERIVATIVES | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1983-11-01 | — | — | US | disclosed |
| EP-0018549-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Tanabe Seiyaku Co., Ltd. (JP) | 1981-12-30 | — | — | EP | disclosed |
| US-4294832-A | HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
| EP-0018549-A2 | Tetrahydroisoquinoline compounds, process for preparing them and pharmaceutical compositions containing them | Tanabe Seiyaku Co., Ltd. (JP) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | GAA 2675/4885MGAM 3943/4885SI 4741/4885 |
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | GAA 592/4885MGAM 558/4885SI 2888/4885 |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | ADRA1D, ADRA1A, VAPA | GAA 2675/4885MGAM 3943/4885SI 4741/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | GAA 2507/4885MGAM 428/4885SI 434/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | GAA 627/4885MGAM 512/4885SI 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.